Universal anti-CD7 CAR-T cells targeting T-ALL and functional analysis of CD7 antigen on T/CAR-T cells

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

(2022) Alan M Williams et al.   BLOOD

CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia

(2021) Yongxian Hu et al.   CLINICAL CANCER RESEARCH

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

(2021) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloid-derived suppressor cells—new and exciting players in lung cancer

(2020) Zhenzhen Yang et al.   Journal of Hematology & Oncology

CD5 dynamically calibrates basal NF-κB signaling in T cells during thymic development and peripheral activation

(2020) Courtney A. Matson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

(2020) Reuben Benjamin et al.   LANCET

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

(2018) Matthew L Cooper et al.   LEUKEMIA

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259 T Cells in Synovial Sarcoma

(2018) Sandra P. D'Angelo et al.   Cancer Discovery

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects

(2010) J. J. Melenhorst et al.   BLOOD